Donchida Srimuan

TL;DR: All four booster vaccines significantly increased binding and NAbs in individuals immunized with two doses of CoronaVac, and the present evidence may benefit vaccine strategies development to thwart variants of concern, including the omicron variant.

TL;DR: Heterologous CoronaVac followed by ChAdOx1-S can be considered as an alternative regimen to homologous efficacy-proven Ch adenoviral vector in countries with circulating variants in light of intermittent supply shortages of individual vaccines.

TL;DR: The reactogenicity of Tdap vaccine administered during pregnancy was not affected by prior tetanus toxoid immunization, and high transplacental antibody against B. pertussis antigens in the cord blood provides evidence of antibody transfer and should thus help to protect newborns from pertussi during early life.

TL;DR: It is demonstrated that mRNA booster vaccination is able to overcome waning immunity to provide antibodies that neutralize omicron BA.1 and BA.2, as well as a T‐cell response.

TL;DR: It is suggested that breakthrough infection after two doses of an inactivated vaccine can induce neutralizing antibody against omicron, and further investigation is needed to assess the long term persistence of antibody against Omicron variant.